ArticleWorld neurosurgery: X2024
Alterations of non-motor symptoms in Parkinson's disease, after of subthalamic deep brain stimulation.
Article in World neurosurgery: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cognitive trajectories in Parkinson's disease patients, a review on the impact of subthalamic deep brain stimulation (STN-DBS) and emerging adaptive strategies.Translational psychiatry · 2026Review
- Long-Term Effects of Deep Brain Stimulation on Non-Motor Symptoms in Patients with Parkinson's Disease.Annals of Indian Academy of Neurology · 2025Article
- Effect of deep brain stimulation on patients with Parkinson's disease with excessive daytime sleepiness.BMJ neurology open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of subthalamic deep brain stimulation (STN DBS) on motor symptoms of Parkinson's disease (PD) has been thoroughly analyzed. The influence of STN DBS on non-motor symptoms (NMS) is still debatable. We analyzed the effect of STN DBS on NMS in PD. Materials and methods: 17 PD patients were qualified for STN DBS according to CAPSIT-PD criteria. Demographic data and clinical status according to the Hoehn-Yahr (H-Y) were recorded. The efficacy of STN DBS on NMS was measured with the NMS Scale before surgery and twelve months after surgery. Results: Global NMS Scale score decreased by 1-75 points (mean 25,67) in 12 patients. No improvement or deterioration was reported in 5 patients (29%). The mean age of the improved group was 56 years and 59,8 years in the non-improved group. The mean duration of PD in the improved group was 11 years and 21 years in the non-improved group. In the non-improved group, four patients were rated 4 and one patients 3 according to the H-Y Scale. In the improved group, two patients were rated 4, six patients 3 and four patients 2 according to the H-Y Scale The most significant improvement of the NMS Scale was recorded in the domain IV- Perceptual problems/Hallucinations- (by 77%), domain I- Cardiovascular including falls- (by 68%) and domain III- Mood/Cognition- (by 58%). Deterioration of the NMS Scale was reported in the domain IX- Miscellaneous- (by 10%) and the domain VII- Urinary- (by 6%). Conclusions: STN DBS has a positive impact on NMS among PD patients. The most important factors that influence improvement are: young age, short disease duration, and good clinical status measured with the H-Y Scale. The NMS Scale domains that tend to respond the best are the domains I, III and IV. The NMS Scale domains that might deteriorate after STN DBS are the domains VII and IX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.